Neuroendocrine carcinoma of the cervix

Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial with BI 764532 in Small Cell Lung Cancer and other Neuroendocrine Cancers

Retrieved on:

Tuesday, October 24, 2023

The Phase 2 study, ‘DAREON™-5’ ( NCT05882058 ) is an open-label, multi-centre, dose-selection study evaluating two doses of BI 764532 in patients with relapsed/refractory extensive-stage SCLC and other relapsed/refractory neuroendocrine carcinomas.

Key Points:

The Phase 2 study, ‘DAREON™-5’ ( NCT05882058 ) is an open-label, multi-centre, dose-selection study evaluating two doses of BI 764532 in patients with relapsed/refractory extensive-stage SCLC and other relapsed/refractory neuroendocrine carcinomas.
Christian Rohlff, PhD, Chief Executive Officer of Oxford BioTherapeutics, said: “The start of this Phase 2 trial with BI 764532, the most advanced candidate with our partner Boehringer Ingelheim which was discovered using our proprietary OGAP® platform, is a major milestone for OBT.
Patients with neuroendocrine carcinomas, including small cell lung cancer, have a 5-year survival rate of approximately 13%.
BI 764532 was discovered using OBT’s proprietary OGAP® drug discovery platform and Boehringer Ingelheim’s longstanding expertise in oncology through a successful partnership initiated in 2013.

Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023

Retrieved on:

Tuesday, September 5, 2023

Carcinoma, Glomus tumor, ESMO, NEPC, European Society for Medical Oncology, Oncology, SCLC, DLL3, Therapy, Neuroendocrine carcinoma of the cervix, Medical imaging

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will host an in-person event “DLL3 Market Opportunity and KOL Discussion of HPN328”, in New York on September 15, 2023 from 8:00 to 9:30 a.m. ET. Invited key opinion leaders (KOLs) will discuss HPN328, a DLL3-targeting tri-specific T cell engager, and its potential in the treatment of small cell lung cancer (SCLC), NEPC (neuroendocrine prostate cancer) and other neuroendocrine carcinomas. The agenda will also include a management overview of the market potential for selected DLL3 expressing tumor types and an update on Harpoon’s clinical development pipeline, including upcoming milestones.

Key Points:

ET.
Invited key opinion leaders (KOLs) will discuss HPN328, a DLL3-targeting tri-specific T cell engager, and its potential in the treatment of small cell lung cancer (SCLC), NEPC (neuroendocrine prostate cancer) and other neuroendocrine carcinomas.
The agenda will also include a management overview of the market potential for selected DLL3 expressing tumor types and an update on Harpoon’s clinical development pipeline, including upcoming milestones.
To register to attend in person, please contact: Maria Yonkoski, [email protected]
To register for the webcast please visit this link:

Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I/II Clinical Study

Retrieved on:

Monday, October 3, 2022

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced today it had received FDA clearance to begin a Phase I/II clinical study utilizing Seneca Valley Virus (SVV-001) in combination with a checkpoint inhibitor.

Key Points:

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced today it had received FDA clearance to begin a Phase I/II clinical study utilizing Seneca Valley Virus (SVV-001) in combination with a checkpoint inhibitor.
This Phase I/II study with SVV-001 is in patients that are TEM8 positive and SVV-001 permissive with neuroendocrine tumors or neuroendocrine carcinomas.
The study should begin enrollment early in 2023.
This press release contains forward-looking statements concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the companys expectations regarding its prospects.

Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck

Retrieved on:

Friday, July 23, 2021

DecisionDx-SCC is Castles prognostic 40-gene expression profile (GEP) test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC), designed to use a patients tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.

Key Points:

DecisionDx-SCC is Castles prognostic 40-gene expression profile (GEP) test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC), designed to use a patients tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.
The data further demonstrate that Castles DecisionDx-SCC test can provide clinicians with additional information on a patients metastatic risk to help them make more informed choices about their treatment and follow-up care.
All SCC tumor specimens were tested with DecisionDx-SCC and analyzed using Kaplan-Meier for metastasis-free survival (MFS) and Cox regression for risk of regional/distant metastasis.
DecisionDx-SCC is a 40-gene expression profile test that uses an individual patients tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors.

Castle Biosciences Announces Publication of Validation Study for DecisionDx-SCC, Showing this Test is an Independent Predictor of Metastatic Risk in Squamous Cell Carcinoma

Retrieved on:

Wednesday, April 29, 2020

Biotechnology, Genetics, Health, Oncology, Cancer, Neoplasms, RTT, Health, Anatomical pathology, Oncology, Lung cancer, Cancer staging, Metástasis, Squamous cell skin cancer, Neuroendocrine carcinoma of the cervix, Cutaneous Squamous Cell Carcinoma, Castle Biosciences

The study results demonstrate that DecisionDx-SCC is an independent predictor of metastatic risk that can complement current cancer risk-factor staging systems for patients with high-risk SCC.

Key Points:

The study results demonstrate that DecisionDx-SCC is an independent predictor of metastatic risk that can complement current cancer risk-factor staging systems for patients with high-risk SCC.
Validation of the DecisionDx-SCC test demonstrates significant progress in this area by integrating tumor-specific genetic information into clinical decision making.
SCC National Comprehensive Cancer Network (NCCN) guidelines define treatment pathways based on risk of local recurrence or metastasis.
For SCC, there are two clinicopathologically defined categories: low risk and high risk.

Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting

Retrieved on:

Tuesday, October 29, 2019

Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Cancer, Medicine, Clinical medicine, Oncology, Radiation therapy, Radioactivity, Radiobiology, Gynaecological cancer, Chemotherapy, DecisionDx-UM, Neuroendocrine carcinoma of the cervix, Cutaneous Squamous Cell Carcinoma, Castle Biosciences

Thus, many high-risk patients may be over-treated with radiation, chemotherapy or other interventions even when they may not be needed.

Key Points:

Thus, many high-risk patients may be over-treated with radiation, chemotherapy or other interventions even when they may not be needed.
There is a clear need for more accurate methods to identify high-risk SCC patients to appropriately direct work-up and treatment plans.
To address this need, Castle Biosciences has developed DecisionDx-SCC, a proprietary 40-gene prognostic test.
The multicenter validation study included 321 patients, of which 93% had one or more high-risk features and 52 patients experienced metastasis.

Advances in radiation therapy extend and improve lives of patients with anal cancer, studies find

Retrieved on:

Thursday, November 8, 2018

Cancer, Infectious causes of cancer, Gastrointestinal cancer, RTT, Anal cancer, Gynaecological cancer, Radiation therapy, Squamous cell carcinoma, Neuroendocrine carcinoma of the cervix, Squamous cell skin cancer

ARLINGTON, Va., Nov. 8, 2018 /PRNewswire/ --Two recent studies find advances in radiation therapy are helping to prolong or improve the lives of people with anal cancer, including those whose cancer has advanced to stage IV.

Key Points:

ARLINGTON, Va., Nov. 8, 2018 /PRNewswire/ --Two recent studies find advances in radiation therapy are helping to prolong or improve the lives of people with anal cancer, including those whose cancer has advanced to stage IV.
Most anal canal cancers are squamous cell carcinomas (SCC) that have not yet spread to other parts of the body.
Roughly 20 percent of anal SCC patients, however, are diagnosed with distant metastatic disease also known as stage IV disease each year.
The patients had been treated with conventional radiation therapy (n=403) or IMRT (n=376), both with concurrent chemotherapy.